Treating haemostatic disorders

Treating Haemostastic Disorders
The most important part of treating haemostatic disorders is to identify bleeding episodes and start appropriate treatment as soon as possible.  This prevents further blood loss and the onset of complications.

The type of treatment will depend on the exact nature of the condition.

Treating congenital haemophilia with inhibitors
The treatment of haemophilia and related clotting disorders has been largely based on replacing the missing clotting factor with a substitute, typically obtained from human plasma or, more recently, recombinant (genetically engineered) preparations. Clotting factor substitutes are normally very effective.
However, because they are ’foreign proteins’, some people develop inhibitors (antibodies) to them and, as a result, become resistant to further treatment.
The presence of inhibitors in a person with haemophilia, the amount (titer) of that inhibitor, and whether the person is a low or a high responder are important determinants of immediate and future therapy.

Treating acquired haemophilia
The type of treatment used to control the bleeding depends on the severity of the bleed and the strength of the inhibitor in the blood.